Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped company decision based on other studies

Conditions

Ulcerative Colitis

Interventions

DRUG: visilizumab

Sponsor

Facet Biotech

Collaborators

[object Object]